Journal of Pharmaceutical Investigation Earns Q1 Ranking With 5.5 Impact Factor

The Journal of Pharmaceutical Investigation, a peer-reviewed publication covering pharmaceutical sciences and drug development research, has confirmed its standing in the upper tier of scholarly publishing after being abstracted and indexed in Science Citation Index Expanded, commonly known as SciSearch, since 2021. The journal’s most recent performance metrics place its impact factor at 5.5 for 2022, a figure that corresponds to a Q1 ranking in the Pharmacology and Pharmacy category, where it sits at position 48 among 278 indexed journals. These indicators matter far beyond simple prestige: they determine which libraries subscribe to a journal, which databases surface its articles to researchers, and how funding agencies and hiring committees weigh publications when evaluating scientific output.

Abstracting and indexing services form the backbone of scientific communication infrastructure. When a journal is abstracted and indexed, its article records, including titles, author names, affiliations, abstracts and bibliographies, are systematically captured and catalogued in large bibliographic databases that researchers around the world use every day. Science Citation Index Expanded, maintained within the Web of Science platform, is one of the most selective and widely consulted of these services. Inclusion signals that a journal has passed editorial quality assessments covering peer-review rigor, publication ethics, editorial board composition, timeliness and international reach. For a pharmaceutical sciences journal, this recognition is particularly consequential because the field spans chemistry, pharmacology, formulation science, clinical investigation and regulatory science, and its researchers rely on comprehensive literature discovery to avoid duplication and build on prior findings.

The mechanics of indexing are less visible to readers but essential to how science circulates. Once a journal is accepted into SciSearch, every published article receives consistent metadata treatment: digital object identifiers are registered, citations between articles are tracked, and bibliometric algorithms can count how often a paper is referenced by later work. This citation network is what makes quantitative measures possible in the first place. Without structured indexing, citation counts would be fragmented across publisher websites and impossible to aggregate reliably. Indexed status also enables discovery through search platforms that institutions license, meaning a clinical pharmacist in Seoul or a formulation scientist in Boston encounters the journal’s content through the same trusted databases rather than through scattered web searches.

The impact factor of 5.5 reported for 2022 is calculated through a well-defined formula: it counts the citations received in that year by articles the journal published in the two preceding years, divided by the number of citable items, typically research articles and reviews, published in those same two years. A value of 5.5 means that, on average, recent articles in the journal were cited more than five times within roughly two years of publication, a strong performance in pharmacology and pharmacy, where citation patterns tend to be steadier and more gradual than in fast-moving fields such as molecular biology. The Q1 designation, derived from the journal’s position at 48 of 278 in its category, means it falls within the top quartile of titles, a threshold many institutions use as a benchmark for high-quality publication.

Within the pharmaceutical research community, these metrics carry practical weight. Journals that rank highly attract manuscripts from established laboratories, which in turn raises the technical quality and relevance of published work, creating a feedback loop of visibility and citation. For authors, publishing in an indexed, Q1-ranked journal ensures that their findings are counted in institutional assessments, grant applications and national research evaluation frameworks, many of which explicitly require Web of Science or Scopus inclusion. For readers, the ranking acts as a quality heuristic, a signal that the peer review process has historically filtered submissions with reasonable strictness. For librarians managing tight budgets, category rank and impact factor often inform subscription and renewal decisions, so a journal’s bibliometric performance directly shapes whether researchers can access it at all.

The journal’s subject area itself explains why this recognition resonates. Pharmaceutical investigation encompasses preclinical drug evaluation, pharmacokinetics and pharmacodynamics, novel delivery systems, nanotechnology-based formulations, biopharmaceutics and translational research linking laboratory findings to clinical outcomes. This is a domain where the pace of innovation is accelerating, driven by biologics, RNA therapeutics, targeted delivery platforms and computational drug design. Researchers in these areas depend on rapid, reliable access to peer-reviewed results, and a journal embedded in the core citation indexes effectively becomes part of the discipline’s shared memory. Articles that might otherwise remain niche become discoverable through citation chains, review articles and database alerts.

Entry into Science Citation Index Expanded in 2021 marked a milestone because that year is the starting point from which the journal’s citation record accumulates in the index. Impact factors for newly indexed journals require a lag period before the citation window contains sufficient data, so the 5.5 figure for 2022 represents the first full measurement of the journal’s citation performance within the service. Achieving a Q1 rank in that early measurement window is notable, since it indicates that work published in the journal was already being cited at a level competitive with long-established titles in pharmacology and pharmacy. It also suggests that the journal’s editorial scope aligns with active research fronts where citation activity is naturally concentrated.

Bibliometric indicators should nevertheless be read with nuance, a point widely acknowledged across the scholarly communication community. An impact factor describes the average citation behavior of a journal’s recent output, not the quality of any individual article, and citation counts vary by article type, topic popularity and review share. A journal publishing influential methodological reviews may see its average lifted relative to one focused on narrow empirical studies. Category rankings are more robust because they compare journals within the same discipline, but they still aggregate across subfields with different citation customs. Researchers and evaluators are therefore encouraged to treat the 5.5 impact factor and Q1 rank as one signal among several, alongside peer review reports, replication records and the actual content of the research itself.

For the journal’s editorial team, sustained indexing brings ongoing obligations. Indexed journals must maintain consistent publication schedules, transparent peer review workflows, correctable article records and adherence to publishing ethics standards. Data integrity, authorship transparency and conflict-of-interest disclosure are scrutinized both at submission and in periodic re-evaluation by indexing services, which can delist journals that fall short. This accountability framework benefits the entire pharmaceutical sciences community: it keeps the citation record trustworthy, ensures that meta-analyses and systematic reviews rest on verifiable sources, and protects early-career researchers who stake their careers on publications whose provenance must withstand institutional scrutiny.

As pharmaceutical research grows more interdisciplinary, the role of well-indexed journals as connective tissue between chemistry, biology, engineering and clinical medicine will only expand. The Journal of Pharmaceutical Investigation’s presence in Science Citation Index Expanded since 2021, combined with its 2022 impact factor of 5.5 and its Q1 standing at 48 of 278 in Pharmacology and Pharmacy, positions it as a reference point for researchers navigating this crowded landscape. Whether these metrics translate into durable scientific influence depends on the quality of the work the journal continues to publish and the rigor of its editorial processes, but the early indicators suggest that its articles are reaching the audiences positioned to build on them, cite them and, ultimately, convert them into better medicines.

Subject of Research: Abstracting, indexing and citation performance of the Journal of Pharmaceutical Investigation in Web of Science and pharmacology journal rankings

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Web of Science, impact factor, Q1 journal, Pharmacology and Pharmacy, pharmaceutical sciences, bibliometrics, scholarly publishing, citation metrics